Monoclonal antibody field

According to estimates by Asian Chemical Biology biomedical analysts, China’s monoclonal antibody market is expected to approach 18 billion yuan by 2020.

The recombinant humanized anti-tumor necrosis factor alpha monoclonal antibody for injection developed by Livzon Monoclonal Antibody for the treatment of rheumatoid arthritis has completed phase I clinical trial and obtained phase II/III clinical approval. The company is actively promoting the clinical work;

In the treatment of malignant tumors such as breast cancer, the recombinant anti-HER2 domain II humanized monoclonal antibody injection submitted by Livzon Monoclonal Antibody has successfully passed the technical review of CDE, and can significantly inhibit the growth of subcutaneous transplantation tumor of human breast cancer cell in nude mice, bringing more hope for the diagnosis and treatment of breast cancer patients. At present, in the field of monoclonal antibody drugs, precise diagnosis and biological targeted drugs have been used to achieve precise treatment of different subtypes of breast cancer clinically.

The approved “Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection” is suitable for immunotherapy of various advanced solid tumors through blocking PD-1/PD-L1 immune checkpoint signaling pathway and promoting T cell Immunological anti-tumor response. The pre-clinical in vivo metabolism basically showed linear dynamic characteristics. The pre-clinical pharmacology and toxicology studies have also showed its good safety and effectiveness. In terms of the international trial of “Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection”, the clinical trial application was officially submitted on June 29, 2017 (U.S. time), accepted by the United States FDA (acceptance number: IND133742) and formally approved on July 28, 2017 (U.S. time).

New breakthroughs in research and development of monoclonal antibodies in the future may surprise the biomedical industry and patients.